Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
November-2018 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2018 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells

  • Authors:
    • Xiao Wei
    • Dan Zhu
    • Chenchen Feng
    • Guofang Chen
    • Xiaodong Mao
    • Qifeng Wang
    • Jie Wang
    • Chao Liu
  • View Affiliations / Copyright

    Affiliations: Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, P.R. China, Department of Endocrinology, Jiangdu People's Hospital of Yangzhou, Yangzhou, Jiangsu 225200, P.R. China, Central Laboratory, Jiangsu Province Blood Center, Nanjing, Jiangsu 210042, P.R. China
    Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 3959-3964
    |
    Published online on: September 7, 2018
       https://doi.org/10.3892/etm.2018.6706
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Cyclosporin A (CsA) is widely used as an immunosuppressor in the context of organ transplantation or autoimmune disorders. Recent studies have revealed the detrimental effects of CsA on insulin resistance and pancreatic β cell failure; however, the molecular mechanisms are unknown. The present study sought to confirm the associations between CsA and β cell failure, and to investigate the roles of proinsulin folding and endoplasmic reticulum (ER) stress in CsA‑induced β cell failure. The viability of MIN6 cells treated with CsA was evaluated with MTT assay. Expression levels of insulin, peptidyl‑prolyl cis‑trans isomerase B (PPIB), cleaved caspase‑3, phospho‑protein kinase R (PKR)‑like endoplasmic reticulum kinase (p‑PERK), PKR‑like endoplasmic reticulum kinase (PERK), binding immunoglobulin protein (BIP), and C/EBP homologous protein (CHOP) were detected via reducing western blot assay. Non‑reducing western blot analysis was performed to examine the expression of misfolded proinsulin peptides. The proliferation of MIN6 cells was not inhibited by CsA at concentrations <1 µmol/l. CsA treatment resulted in the decreased expression of insulin and PPIB; however, it also increased the phosphorylation of PERK, and upregulated the expression of PERK, BIP, CHOP and cleaved caspase‑3. The results indicated that CsA could induce pancreatic β cell dysfunction and the potential mechanism underlying this phenomenon may be PPIB‑associated proinsulin misfolding, which in turn induces ER stress in β cells.

Introduction

Cyclosporin A (CsA) is widely used as an immunosuppressor, but clinical study found that after organ transplantation diabetes mellitus associated with the use of immunosuppressants (1,2). New-onset diabetes mellitus (NODM) is an important complication among patients receiving immunosuppressants. Clinical studies have found that CsA induces hyperglycemia and decreased plasma insulin levels in organ transplant patients (3–5). The diabetogenicity of cyclosporin has been attributed to both impaired insulin sensitivity and β cell function (6–8). Animal experiments have confirmed that CsA induces insulin resistance by decreasing the cell surface availability of glucose transporter 4 (GLUT4) (9). Some research suggests that CsA and tacrolimus are Ca2+ inhibitors. They likely affect insulin secretion in β cell function, but previous studies have confirmed that CsA maybe induces β cell apoptosis by other mechanisms. Therefore, this research aims to confirm CsA induces β cell apoptosis by specific inhibition of PPIB which could cause the proinsulin misfolded. It is important to know the mechanism of CsA and prevent NODM.

Recent studies have demonstrated that CsA adversely affects pancreatic β cells and activates endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), thus leading to cell death (10). However, the mechanisms through how CsA induces ER stress remain largely unknown, but the ER stress in β cells could be caused by misfolded proinsulin. Pancreatic islet β cells synthesize and secrete insulin and regulate blood glucose concentrations. The post-translational modification of insulin involves two steps. First, insulin mRNA is translated as a single-chain precursor called preproinsulin, and the removal of this precursor's signal peptide during insertion into the ER generates proinsulin (11). Second, proinsulin is cleaved into insulin and C-peptide. There are three intramolecular disulfide bonds in proinsulin and insulin molecules; these bonds are important for insulin bioactivity. Similarly to disulfide bonds in many secretory proteins, these bonds help to stabilize molecules before and after secretion. The proinsulin molecule is folded in the ER; during this process, the three aforementioned evolutionarily conserved disulfide bonds are formed. Properly folded proinsulin forms dimers and exits the ER, trafficking through the golgi complex into secretory granules, where prohormone convertases (PC1/3 and PC2) (12), in concert with carboxypeptidase E (CPE), process proinsulin into C-peptide and two-chain mature insulin, which is stored in insulin granules (13).

PPIase family proteins are isomerases that shuffle disulfide bonds and allow proinsulin molecules to potentially reach their native conformation. Peptidyl-prolyl cis-trans isomerase b (PPIB) is a member of the cyclophilin-type PPIase family and contributes to protein folding (14–16). If proinsulin is not properly folded within the ER, ER stress-induced cell apoptosis occurs. CsA is not only an immunosuppressant but also a known inhibitor of PPIB (17,18). PPIB may be the key player in CsA-induced β cell death and may be involved in the molecular mechanism through which unfolded proinsulin activates ER stress.

Materials and methods

Reagents and antibodies

CsA and palmitic acid (PA) were purchased from Sigma (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). PA/Bull Serum Albumin (BSA) conjugates were prepared as described previously. Briefly, a 100 mmol/l solution of PA in 0.1 N NaOH was incubated at 70°C for 30 min, and fatty acid soaps were then complexed with 5% BSA in PBS at a 19:1 molar ratio of fatty acids to BSA. CsA was dissolved in PBS to obtain a 10 mmol/l stock solution. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was obtained from Biosharp (Sigma-Aldrich; Merck KGaA). Primary antibodies, including anti-insulin (1:1,000; cat. no. 8138), anti-caspase-3 (1:2,000; cat. no. 9662), anti-phospho-PKR-like endoplasmic reticulum kinase (p-PERK; 1:1,000 cat. no. 3179), anti-PKR-like endoplasmic reticulum kinase (PERK; 1:2,000; cat. no. 3192), anti-binding immunoglobulin protein (BIP; 1:3,000; cat. no. 3183), and anti-C/EBP homologous protein (CHOP; 1:3,000; cat. no. 2895) and anti-β-actin antibodies (1:5,000; cat. no. 3700), and secondary antibodies anti-rabbit IgG (1:2,000; cat. no. 7074) and anti-mouse IgG (1:2,000; cat. no. 7076) were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-C-peptide (cat. no. ab14181; 1:1,000) and anti-PPIB primary antibodies (cat. no. ab16045; 1:1,000) were obtained from Abcam (Cambridge, UK).

Cell culture

MIN6 mouse insulinoma cells were obtained from the Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University (Nanjing, China), and cultured in Dulbecco's modified Eagle's medium (DMEM), a high-glucose culture medium, supplemented with 15% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 50 µmol/l 2-mercaptoethanol (Sigma-Aldrich; Merck KGaA), 100 U/ml penicillin and 100 U/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.). These cells were incubated in a humidified atmosphere of 5% CO2 and 95% air at 37°C.

Cell viability assay

Cells were seeded in 96-well plates at a density of 103 cells per well and continuously exposed to CsA, PA or a combination of both drugs. Twenty-four hours later, the cells were treated with MTT (5 mg/ml) at 37°C for 4 h. Culture medium containing MTT was discarded, and DMSO was added to each well to dissolve the precipitate. Absorbance values were measured at a spectral wavelength of 570 nm using a microplate reader after the plates were incubated with vibration at 37°C for15 min.

Western blot analysis

After treatment, MIN6 cells (5×106 cells) were washed with PBS three times and lysed in RIPA lysis buffer (25 mmol/l HEPES, 1.5% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.5 M NaCl, 5 mmol/l EDTA, 50 mM NaF, 0.1 mmol/l sodium vanadate, and 1 mmol/l phenylmethylsulfonyl fluoride, pH 7.8) on ice for 30 min. The cell lysate was centrifuged at 12,000 rpm for 30 min at 4°C, and the protein concentration in the supernatant was determined via a BCA assay. Reducing loading buffer or non-reducing loading buffer (lacked DTT and 2-mercaptoethanol; both Beyotime Institute of Biotechnology, Shanghai, China) was added to the supernatant, which was subsequently boiled for 5 min and then electrophoresed on a 12.5 or 10% SDS-PAGE gel. Proteins were transferred to a PVDF membrane, and non-specific binding sites were blocked with 5% nonfat dry milk in PBST (PBS containing 0.05% Tween-20) for 2 h. The membrane was then incubated with primary antibodies: Insulin, C-peptide, PPIB, caspase-3, p-PERK, PERK, BIP, CHOP overnight at 4°C and then with peroxidase-conjugated secondary antibodies at room temperature for 2 h. A sequential enhanced chemiluminescence reagent was used to detect bands.

Statistical analysis

SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used to assess study data via one-way analysis of variance followed by Dunnett's t-test or an LSD test. All experiments were performed three times, and the results are presented as means ± standard deviation. Differences were regarded as significant if P<0.05.

Results

The effect of CsA on the viability of MIN6 cells

The viability of MIN6 cells was decreased by CsA. There were no significant differences between the CsA and control groups at CsA concentrations lower than 1 µmol/l (Fig. 1).

Figure 1.

Effect of CsA on the viability of MIN6 cells. Cells were treated with different concentrations of CsA for 24 h, and cell viability was determined via MTT assays. *P<0.05 and ***P<0.001 vs. NC group. NC, normal control; CsA, cyclosporin A.

CsA inhibits the expression of insulin and PPIB and increases the misfolding of proinsulin peptides in MIN6 cells

After MIN6 cells were treated with different concentrations of CsA for 24 h (Fig. 2), the protein expression of PPIB was decreased (P<0.05; Fig. 2C). Additionally, insulin expression in MIN6 cells was decreased (P<0.05; Fig. 2A), whereas the expression of misfolded proinsulin peptides was increased (P<0.05; Fig. 2B).

Figure 2.

CsA inhibits the expression of insulin, proinsulin and PPIB in MIN6 cells. (A) Following MIN6 cell treatment with different concentrations of CsA for 24 h, insulin expression was determined via a reducing western blot assay. (B) In addition, the levels of misfolded proinsulin peptides were determined via a non-reducing western blot assay. (C) The expression of PPIB also decreased with increasing treatment. *P<0.05 and **P<0.01 vs. NC group. NC, normal control; CsA, cyclosporin A; PPIB, peptidyl-prolyl cis-trans isomerase B.

CsA and PA upregulate ER stress and the expression of apoptosis-related proteins

Cells were treated with CsA, PA or a combination of both drugs for 24 h (Fig. 3). Cleaved caspase-3, p-PERK, PERK, BIP and CHOP were upregulated after the cells were exposed to CsA or PA (P<0.05; Fig. 3A and C). Thus, CsA and PA induced ER stress-related apoptosis in MIN6 cells. The expression of PPIB and insulin was inhibited by treatment with these two drugs. Additionally, both CsA and PA caused the upregulation of misfolded proinsulin peptides but the downregulation of insulin expression (P<0.05; Fig. 3B).

Figure 3.

CsA and PA upregulate ER stress and the expression of apoptosis-associated proteins. (A) MIN6 cells were treated with 1 µmol/l CsA, 0.5 mmol/l PA or a combination of the two for 24 h. The expression of ER stress-induced cell apoptosis-associated proteins (cleaved caspase-3, p-PERK, PERK, BIP and CHOP) and insulin was then determined via a western blot assay. (B) Misfolded proinsulin peptides were detected via a non-reducing western blot assay. (C) The relative protein levels of cleaved caspase-3, p-PERK, BIP and CHOP were upregulated, and those of PPIB and insulin were downregulated. *P<0.05, **P<0.01 and ***P<0.001 vs. NC, or as indicated. NC, normal control; CsA, cyclosporin A; PA, palmitic acid; ER, endoplasmic reticulum; p-, phosphorylated; PERK, protein kinase R-like endoplasmic reticulum kinase; BIP, binding immunoglobulin protein; CHOP, C/EBP homologous protein; PPIB, peptidyl-prolyl cis-trans isomerase B.

Discussion

Cyclophilins are a family of proteins present in vertebrates and other organisms. They bind to CsA, an immunosuppressant that is commonly used to suppress rejection after organ transplantation (19–20). The molecular mechanisms of CsA-induced β cell apoptosis probably involve the downregulation of cyclophilins.

This study in our research, MIN6 cells were treated with different concentrations of CsA (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50 and 100 µmol/l). There were no significant differences between the control and 1 µmol/l CsA group. The results reveal after treatment with CsA concentrations lower than 1 µmol/l. There is a limitation of the current study, we should be confirmed the apoptosis in some ways such as flow cytometry, but we have already detected the expression of cleaved caspase-3. MIN6 cells were treated with CsA for 24 h has obviously changes in apoptosis. So we chose this time point (other time points not show). We used chose three concentrations of CsA (0.1, 1 and 10 µmol/l) to study the resultant effects on proinsulin folding.

In order to reveal the molecular mechanism of CsA induced MIN6 apoptosis, proinsulin folding and UPR were detected. Reducing and non-reducing SDS-PAGE assays were used to examine the expression of misfolded proinsulin peptides. The reducing SDS-PAGE buffer contained mercaptoethanol, which reduces disulfide bonds and breaks down the complex structure of proinsulin. Meanwhile the non-reducing SDS-PAGE-based western blot assay does not break misfolded peptides into monomers (21,22). Proinsulin has two forms in the ER: the correctly folded monomer and misfolded proinsulin peptides. Misfolded proinsulin peptides produce insoluble polymers of various molecular weights (23). Only correctly folded monomers can be cleaved into mature insulin (24). Proinsulin peptides of different molecular weights can be detected via a non-reducing western blot assay. Our results demonstrated that CsA decreased the expression of insulin and increased the expression of misfolded proinsulin peptides. These findings suggest that in cells treated with CsA, insulin mRNA can be translated into proinsulin; however, this proinsulin could not become insulin in the ER. CsA also down regulated the expression of PPIB. PPIB could potential be a key protein involved in proinsulin folding. We revealed the relationship between proinsulin and PPIB, but further studies are needed to investigate the potential direct association between them.

Proinsulin misfolding maybe the initial factor causing β cell failure. If nonfunctional peptides accumulate in the ER, ER stress-induced cell apoptosis occurs (25). To study the effect of misfolded peptides in the ER. PA was used as a positive control for ER stress (26,27). Certain ER stress-related proteins were detected in response to PA treatment. CsA and PA can both increase misfolded peptides, cleaved caspase-3, p-PERK, PERK, BIP and CHOP. We was suggested to detect the mRNA levels at same time to make a strong conclusion, and it will be accepted in further research. These findings indicate that ER stress is activated in response to an accumulation of unfolded or misfolded proteins in the lumen of the ER (28–30). Our data also revealed that ER stress was induced by CsA and PA, both of which had similar effects on proinsulin folding and ER stress (Fig. 4).

Figure 4.

CsA induces β cell dysfunction, and downregulates the expression of PPIB. A schematic of the potential mechanism underlying how PPIB related proinsulin misfolding can induce ER stress in β cells. CsA, cyclosporin A; PPIB, peptidyl-prolyl cis-trans isomerase B; ER, endoplasmic reticulum.

The purpose of this paper is to prove that the proinsulin-fold disorder and endoplasmic reticulum stress occur at the same time. A reasonable possible mechanism between proinsulin and endoplasmic reticulum stress was mentioned in this manuscript. Further research is needed to confirm the potential mechanism. In conclusion, CsA induces β cell dysfunction and downregulates the expression of PPIB. The reasonable underlying mechanism of this phenomenon may be that PPIB-related proinsulin misfolding induces ER stress in β cells.

Acknowledgements

The authors would like to acknowledge The Key Laboratory of TCM Syndrome and Treatment of Yingbing of State Administration of Traditional Chinese Medicine (Nanjing, China) and Research Center of Endocrine and Metabolic Diseases (Jiangsu, China) for the use of their laboratories. In addition, the authors would like to thank Dr Xingjia Li, Dr Yu Chen, Dr Yijiao Xu and Dr Wanwei Yang (Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) for their useful advice and assistance.

Funding

The present study was supported by The National Natural Science Foundation of China (grant no. 81270861) and Foundation Research Project of Jiangsu Province (The Natural Science Fund, grant no. BK2012887).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

GC, JW and CL designed research. XW, DZ, XM and QW performed the experiments. CF analyzed the data, and XW and CF wrote the manuscript. All authors discussed the results and reviewed the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Shivaswamy V, Boerner B and Larsen J: Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes. Endocr Rev. 37:37–61. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Wang X, Hu YC, Zhang RY, Jin DX, Jiang Y, Zhang HN and Cong HL: Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis. Exp Ther Med. 12:3242–3248. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Bhat M, Pasini E, Copeland J, Angeli M, Husain S, Kumar D, Renner E, Teterina A, Allard J, Guttman DS and Humar A: Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: A systems biology approach to post-transplant diabetes. Sci Rep. 7:102772017. View Article : Google Scholar : PubMed/NCBI

4 

Azzi JR, Sayegh MH and Mallat SG: Calcineurin inhibitors: 40 years later, can't live without. J Immunol. 191:5785–5791. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Langsford D and Dwyer K: Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes, and implications for management. World J Diabetes. 6:1132–1151. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Montero N and Pascual J: Immunosuppression and Post-transplant Hyperglycemia. Curr Diabetes Rev. 11:144–154. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Palepu S and Prasad GV: New-onset diabetes mellitus after kidney transplantation: Current status and future directions. World J Diabetes. 6:445–455. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA and Rungby J: Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 162:136–146. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK and Eriksson JW: Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: Increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab. 99:E1885–E1894. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Bai Y, Wei Y, Wu L, Wei J, Wang X and Bai Y: C/EBP β mediates endoplasmic reticulum stress regulated inflammatory response and extracellular matrix degradation in LPS-stimulated human periodontal ligament cells. Int J Mol Sci. 17:3852016. View Article : Google Scholar : PubMed/NCBI

11 

Liu M, Wright J, Guo H, Xiong Y and Arvan P: Proinsulin entry and transit through the endoplasmic reticulum in pancreatic beta cells. Vitam Horm. 95:35–62. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Ozawa S, Katsuta H, Suzuki K, Takahashi K, Tanaka T, Sumitani Y, Nishida S, Yoshimoto K and Ishida H: Estimated proinsulin processing activity of prohormone convertase (PC) 1/3 rather than PC2 is decreased in pancreatic β-cells of type 2 diabetic patients. Endocr J. 61:607–614. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Zhang X, Yuan Q, Tang W, Gu J, Osei K and Wang J: Substrate-favored lysosomal and proteasomal pathways participate in the normal balance control of insulin precursor maturation and disposal in β-cells. PLoS One. 6:e276472011. View Article : Google Scholar : PubMed/NCBI

14 

Kim G, Kim JY and Choi HS: Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a therapeutic target in hepatocellular carcinoma. Biol Pharm Bull. 38:975–979. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Ren LQ, Liu W, Li WB, Liu WJ and Sun L: Peptidylprolyl cis/trans isomerase activity and molecular evolution of vertebrate cyclophilin A. Yi Chuan. 38:736–745. 2016.PubMed/NCBI

16 

Humbert MV, Mendoza Almonacid HL, Jackson AC, Hung MC, Bielecka MK, Heckels JE and Christodoulides M: Vaccine potential of bacterial macrophage infectivity potentiator (MIP)-like peptidyl prolyl cis/trans isomerase (PPIase) proteins. Expert Rev Vaccines. 14:1633–1649. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Cho KI, Orry A, Park SE and Ferreira PA: Targeting the cyclophilin domain of Ran-binding protein 2 (Ranbp2) with novel small molecules to control the proteostasis of STAT3, hnRNPA2B1 and M-opsin. ACS Chem Neurosci. 6:1476–1485. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Ernst K, Langer S, Kaiser E, Osseforth C, Michaelis J, Popoff MR, Schwan C, Aktories K, Kahlert V, Malesevic M, et al: Cyclophilin-facilitated membrane translocation as pharmacological target to prevent intoxication of mammalian cells by binary clostridial actin ADP-ribosylated toxins. J Mol Biol. 427:1224–1238. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Tafazoli A: Cyclosporine use in hematopoietic stem cell transplantation: Pharmacokinetic approach. Immunotherapy. 7:811–836. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Wang Z and Zhang L: Treatment effect of cyclosporine A in patients with painful bladder syndrome/interstitial cystitis: A systematic review. Exp Ther Med. 12:445–450. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Wang J and Osei K: Proinsulin maturation disorder is a contributor to the defect of subsequent conversion to insulin in β-cells. Biochem Biophys Res Commun. 411:150–155. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Wang J, Chen Y, Yuan Q, Tang W, Zhang X and Osei K: Control of precursor maturation and disposal is an early regulative mechanism in the normal insulin production of pancreatic β-cells. PLoS One. 6:e194462011. View Article : Google Scholar : PubMed/NCBI

23 

Yuan Q, Tang W, Zhang X, Hinson JA, Liu C, Osei K and Wang J: Proinsulin atypical maturation and disposal induces extensive defects in mouse Ins2+/Akita β-cells. PLoS One. 7:e350982012. View Article : Google Scholar : PubMed/NCBI

24 

Fu Z, Gilbert ER and Liu D: Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 9:25–53. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Chan JY, Luzuriaga J, Maxwell EL, West PK, Bensellam M and Laybutt DR: The balance between adaptive and apoptotic unfolded protein responses regulates β-cell death under ER stress conditions through XBP1, CHOP and JNK. Mol Cell Endocrinol. 413:189–201. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Yu C, Cui S, Zong C, Gao W, Xu T, Gao P, Chen J, Qin D, Guan Q, Liu Y, et al: The orphan nuclear receptor NR4A1 protects pancreatic β-cells from endoplasmic reticulum (ER) stress-mediated apoptosis. J Biol Chem. 290:20687–20699. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Kwak HJ, Choi HE, Jang J, Park SK, Bae YA and Cheon HG: Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism. Cell Signal. 28:788–797. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Oh YS, Lee YJ, Kang Y, Han J, Lim OK and Jun HS: Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors. J Endocrinol. 216:343–352. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Cumaoglu A, Arıcıoglu A and Karasu C: Redox status related activation of endoplasmic reticulum stress and apoptosis caused by 4-hydroxynonenal exposure in INS-1 cells. Toxicol Mech Methods. 24:362–367. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Reid DW, Chen Q, Tay AS, Shenolikar S and Nicchitta CV: The unfolded protein response triggers selective mRNA release from the endoplasmic reticulum. Cell. 158:1362–1374. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wei X, Zhu D, Feng C, Chen G, Mao X, Wang Q, Wang J and Liu C: Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells. Exp Ther Med 16: 3959-3964, 2018.
APA
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q. ... Liu, C. (2018). Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells. Experimental and Therapeutic Medicine, 16, 3959-3964. https://doi.org/10.3892/etm.2018.6706
MLA
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q., Wang, J., Liu, C."Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells". Experimental and Therapeutic Medicine 16.5 (2018): 3959-3964.
Chicago
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q., Wang, J., Liu, C."Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells". Experimental and Therapeutic Medicine 16, no. 5 (2018): 3959-3964. https://doi.org/10.3892/etm.2018.6706
Copy and paste a formatted citation
x
Spandidos Publications style
Wei X, Zhu D, Feng C, Chen G, Mao X, Wang Q, Wang J and Liu C: Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells. Exp Ther Med 16: 3959-3964, 2018.
APA
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q. ... Liu, C. (2018). Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells. Experimental and Therapeutic Medicine, 16, 3959-3964. https://doi.org/10.3892/etm.2018.6706
MLA
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q., Wang, J., Liu, C."Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells". Experimental and Therapeutic Medicine 16.5 (2018): 3959-3964.
Chicago
Wei, X., Zhu, D., Feng, C., Chen, G., Mao, X., Wang, Q., Wang, J., Liu, C."Inhibition of peptidyl‑prolyl cis‑trans isomerase B mediates cyclosporin A‑induced apoptosis of islet β cells". Experimental and Therapeutic Medicine 16, no. 5 (2018): 3959-3964. https://doi.org/10.3892/etm.2018.6706
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team